Navigation Links
Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
Date:1/11/2008

FDA Warns Pharmacies Not to Compound Commonly-Prescribed Hormone Estriol,

Not to Use the Term 'Bio-identical'

SPOKANE, Wash., Jan. 11 /PRNewswire/ -- "The FDA statement regarding compounded estrogens -- which include estradiol and estriol -- progesterone, and other compounded hormones was very surprising to me and other medical experts in the field of Women's Hormones," remarks Cheryle Hart, M.D. She is Mayo Clinic trained and Board certified in Ob/Gyn and founded what is now Hormones by Hart in 1997. She is also the medical director of Hormones by Hart.

The FDA stated on January 9, 2008 that pharmacies cannot use the term "bio-identical" to describe the hormones they are compounding. "Even though the hormones they are using are actually chemically identical to what is produced by the human body," says Dr. Hart.

"I am astounded that the FDA does not recognize that estradiol, progesterone, testosterone, and DHEA are chemically identical to hormones found in our bodies, and are therefore bio-identical. I don't know what 'substantial evidence' they are waiting for to figure that one out."

According to their news release, the FDA does not approve of the use of the estrogen estriol in any compounded formula. They consider this the manufacture of an unapproved drug. "This is certainly news to me, since estriol is one of the types of hormones naturally found in a woman's body. For the FDA to say that menopausal women cannot benefit from the use of Estriol in HRT amazes me. I would certainly like the FDA to reconsider the published evidence on this estrogen and change their ruling," comments Dr. Hart.

Because of the misleading title of the FDA News release, Dr. Hart wants to reassure her patients that while it sounds like FDA is banning compounded bio-identical hormones, it is not banning the compounded hormones.

"It is really up to the compounding pharmacies and their organizations, PCCA and IACP to get this straightened out with the FDA. Since the FDA's new position is that compounds containing estriol represent a 'new drug' it would be improper for me or any other medical practitioner to continue to prescribe Estriol compounds at this time," says Cheryle Hart, M.D.


'/>"/>
SOURCE Cheryle R. Hart, M.D.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
4. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
5. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
6. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
7. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
8. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
9. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
10. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical ... cancer therapeutics designed to target cancer stemness pathways, today ... S. Andrews as Chief Executive Officer, effective April ... Chiang J. Li , M.D., FACP, who has ... years ago. Under his leadership, Boston Biomedical has grown ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
(Date:3/7/2017)... -- Brandwatch , the leading social intelligence company, today announces ... to uncover insights to support its reporting, help direct future campaigns, ... leading youth charity will be using Brandwatch Analytics social listening and ... understanding of the topics and issues that are a priority for ... "Until ...
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
Breaking Biology News(10 mins):